ADMA Biologics' SEC filings document its specialty biologics business through Form 8-K reports on operating and financial results, FDA-related disclosures for ASCENIV, Regulation FD materials and other material-event updates. These records include disclosures tied to product revenue trends, immune globulin market conditions, commercial distribution, plasma collection and biomanufacturing operations.
ADMA's definitive proxy materials cover annual meeting matters, board and governance proposals, voting procedures and executive compensation. Its current reports also document executive transitions, related agreements, capital-structure matters, share-repurchase activity and risk-oriented product disclosures associated with immune globulin products.
ADMA Biologics Inc: The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock. The amendment states that, following an 01/12/2026 internal realignment, certain Vanguard subsidiaries now report holdings separately and The Vanguard Group no longer reports beneficial ownership of those subsidiary holdings.
The filing is an ownership clarification by an institutional investor and does not disclose purchases or sales of ADMA shares in this amendment.
ADMA Biologics director Lawrence P. Guiheen reported a mix of option exercises and charitable estate planning transactions. On March 13, 2026, he exercised stock options to acquire 30,000 shares of common stock at $3.66 per share, increasing his direct equity stake. On March 17, 2026, he made bona fide gifts totaling 60,000 shares of common stock, including 30,000 shares transferred directly and 30,000 shares gifted to the 2019 Guiheen Irrevocable Trust, over which he retains control but disclaims beneficial ownership except for any pecuniary interest. After these transactions, he holds 105,520 shares directly, with additional shares held indirectly through irrevocable trusts as described in the footnotes.
ADMA Biologics President and CEO Adam S. Grossman exercised stock options for 15,000 shares of common stock at $5.40 per share on March 16, 2026, then sold 21,000 shares of common stock at $15.16 per share in open-market transactions.
The filing shows these trades were effected under a Rule 10b5-1 trading plan entered into on November 14, 2025. After the transactions, Grossman holds 2,112,777 shares of ADMA Biologics common stock directly, while entities Areth, LLC and Hariden, LLC hold 1,143,426 and 580,957 shares indirectly associated with him.
ADMA Biologics submitted a Form 144 notice proposing the sale of Common Stock. The filing lists multiple blocks of restricted stock units scheduled to vest on specific dates, including 15,162 shares vesting 06/26/2024 and another 15,162 shares vesting 06/26/2025. The broker/agent listed is Fidelity Brokerage Services, LLC (10b5-1 Group).
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported multiple stock transactions. She exercised stock options to acquire 10,096 shares of common stock at exercise prices ranging from $1.55 to $5.00 per share. In connection with restricted stock unit vesting, 14,294 shares were withheld to cover mandatory tax obligations, which did not involve open-market sales. She also transferred 91,266 shares and sold 10,096 shares of common stock at a weighted average price of $15.63 per share, both carried out under a court-approved divorce settlement. Following these transactions, she directly owned 466,600 shares of ADMA Biologics common stock.
ADMA Biologics President and CEO Adam S. Grossman reported tax-related share withholdings rather than market trades. On March 6–7, 2026, a total of 85,951 shares of Common Stock were withheld at $15.39 per share to satisfy mandatory tax obligations upon vesting of restricted stock units, as noted in the footnotes. After these withholdings, he directly held 2,118,777 shares of Common Stock. Separate holding entries show additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities over which he has control roles.
ADMA Biologics submitted a Form 144 reporting proposed sales of Common Stock tied to option exercises, all dated 03/09/2026. The submission lists five exercise lots: 2,500, 1,250, 2,646, 1,525, and 2,175 shares, each described as "Stock Option Exercise" with the original grant dates shown.
ADMA Biologics director-affiliated funds reported open-market purchases of common stock. Entities associated with director Steve Elms bought a total of 14,000 ADMA shares, with 7,000 shares purchased on March 5, 2026 at a weighted average price of $15.67 per share and 7,000 shares on March 6, 2026 at a weighted average price of $15.39 per share.
The filing notes these shares are held by Aisling Capital II LP and Aisling Arcturus Partners, LP, and that Mr. Elms may be deemed a beneficial owner through his roles at Aisling entities while disclaiming beneficial ownership except to the extent of his pecuniary interest. Following these transactions, Aisling-related entities reported 2,045,730 shares, while Mr. Elms also directly holds 87,330 shares and 10,690 restricted stock units that are scheduled to fully vest on February 9, 2027, subject to continued service.
ADMA Biologics President and CEO Adam S. Grossman reported a tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 54,858 shares of common stock were withheld at $15.18 per share to satisfy mandatory tax withholding obligations, and this was explicitly noted as not an open market sale.
After this withholding, Grossman directly owned 2,204,728 shares of ADMA common stock. He also had indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities for which he is disclosed as a control person or managing member.
ADMA Biologics entered a $125 million accelerated share repurchase agreement with JPMorgan Chase Bank as part of its previously authorized $500 million share repurchase program. The company will fund the transaction with borrowings under its existing $225 million revolving credit facility.
ADMA expects to receive about 6.4 million shares of common stock around March 3, 2026, representing roughly 80% of the shares tied to this agreement, based on a closing share price of $15.57 on February 27, 2026. The final share count will depend on the average daily volume‑weighted average price over the ASR term and is expected to be settled within five months, which could result in ADMA receiving additional shares or delivering shares or cash at final settlement.
The company also outlined a 2026 capital return initiative targeting approximately $200 million, noting that, since the program’s May 2025 authorization, prior repurchases plus this ASR represent about $160 million of common stock repurchased. Management highlights sustained revenue growth, expanding margins and anticipated stronger cash flow as support for continuing to invest in growth while returning capital to stockholders.